Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
EVEvotec SE logo

Evotec SE (EVO)

NASDAQ Global Select · Currency in USD
$1.50 ▼ -0.04 (-2.60%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.53 ▲ +0.03 (+1.91%)
Pre-market: Oct 26, 8:52 AM ET

Summary

Previous Close
$1.54
Open
$1.52
Day's Range
$1.50 – $1.53
52 Week Range
$1.33 – $4.27
Volume
20,606
Avg. Volume
91,819
Market Cap
$532.77M
Beta (5Y Monthly)
1.26
PE Ratio (TTM)
--
EPS (TTM)
-$0.55
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
$3.47 (231.04%)
Ex-Dividend Date
Jan 11, 2019
1y Target Est
$3.00

Profile: Evotec SE

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
4,553
CEO
Christian Wojczewski
Website
evotec.com

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.20 · Revenue est. $155.20M
DateEst.Actual
Aug 13, 2026-$0.05-$0.17Miss
May 6, 2026-$0.15-$0.46Miss
Apr 8, 2026$0.21$0.05Miss
Nov 5, 2025-$0.14-$0.14Miss
Aug 13, 2025-$0.18-$0.14Beat
May 6, 2025-$0.11-$0.15Miss

Analyst view

Consensus price target
$3.00 ▲ +100.0%
Range $2.00 – $4.00
Rating: Buy
Buy 57% · Hold 43% · Sell 0%

Get free alerts on EVO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.